Follow The Filings

AKTS Aktis Oncology

Aktis Oncology earnings company data as of 7:04 PM ET 11/19

  • 0 of 2 EPS beats

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2027 Q1 12 Nov EPS -0.45 -0.54 Miss
Rev $2.5M — —
FY2026 Q2 13 Aug EPS -0.43 -0.44 Miss
Rev — $3.4M —

Insider trades

Open-market buys and sales by AKTS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AKTS insider trades
  • $114M bought by 6 insiders
  • $3M sold by 3 insiders outside a trading plan
  • $259K sold by 1 insider under 10b5-1 plans
  1. Akos Czibere Chief Medical Officer
    Planned sale
    $259K 12,500 shares at $20.69 100% of stake
    Traded Sep 23 Filed Sep 24
  2. Ken Herrmann Director
    Sale
    $119K 4,856 shares at $24.56 100% of stake
    Traded Jul 20 Filed Jul 21
  3. Ken Herrmann Director
    Sale
    $77K 3,065 shares at $25.21 100% of stake
    Traded Jul 17 Filed Jul 20
  4. Shulamit Ron-Bigger COO
    Sale
    $1.4M 50,000 shares at $27.75 100% of stake
    Traded Jul 8 Filed Jul 10
  5. Akos Czibere Chief Medical Officer
    Sale
    $1.4M 50,000 shares at $27.77 100% of stake
    Traded Jul 8 Filed Jul 10
  6. Todd Foley Director
    Buy
    $4.2M 232,870 shares at $18.00 +5.8% to stake
    Traded Jan 12 Filed Jan 14
  7. Mpm Bioventures 2018, L.P. 10% owner, +7 joint filers
    Buy
    $20M 1,112,777 shares at $18.00 +12% to stake
    Traded Jan 12 Filed Jan 14
  8. Vida Ventures II, LLC 10% owner, +1 joint filer
    Buy
    $15M 835,000 shares at $18.00 New stake
    Traded Jan 12 Filed Jan 12
  9. EcoR1 Capital, LLC Director, +1 joint filer
    Buy
    $40M 2,222,222 shares at $18.00 New stake
    Traded Jan 12 Filed Jan 12

Also filed in the last 12 months, not counted as buying or selling: 17 conversions and 7 option exercises.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
SCHEDULE 13G —
10-Q
8-K 2.02,9.01
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
8-K 2.02,9.01
10-Q
8-K 5.02,7.01,9.01
10-K
8-K 2.02,9.01
SCHEDULE 13D —
SCHEDULE 13D —
SCHEDULE 13D —
SCHEDULE 13D —
8-K 5.03,9.01
424B4
S-1/A
S-1/A
S-1

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf